EBSCO Logo
Connecting you to content on EBSCOhost
Results
Title

Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B.

Authors

Sobhonslidsuk, Abhasnee; Numthavaj, Pawin; Wanichanuwat, Jirachaya; Sophonsritsuk, Areepan; Petraksa, Supanna; Pugasub, Alongkorn; Jittorntam, Paisan; Kongsomgan, Anucha; Roytrakul, Sittiruk; Phakdeekitcharoen, Bunyong

Abstract

Aims. Proximal renal tubular dysfunction (PRTD) is an infrequent complication after nucleotide analogue therapy. We evaluated the outcomes of PRTD and nephrotoxicity after nucleotide analogue withdrawal in chronic hepatitis B (CHB). Methods. A longitudinal follow-up study was performed in patients with PRTD after nucleotide analogue discontinuation. Serum and urine were collected at baseline and every 3 months for one year. The fractional excretion of phosphate (PO4), uric acid (UA), and potassium and tubular maximal reabsorption rate of PO4 to glomerular filtration rate (TmPO4/GFR) were calculated. Renal losses were defined based on the criteria of substance losses. Subclinical PRTD and overt PRTD were diagnosed when 2 and ≥3 criteria were identified. Results. Eight subclinical and eight overt PRTD patients were enrolled. After nucleotide analogue withdrawal, there were overall improvements in GFR, serum PO4, and UA. Renal loss of PO4, UA, protein, and β2-microglobulin reduced over time. At one year, complete reversal of PRTD was seen in 13 patients (81.2%). Improvements in PRTD were seen in all but one patient. Conclusion. One year after nucleotide analogue withdrawal, PRTD was resolved in most patients. Changes in TmPO4/GFR, urinary protein, and β2-microglobulin indicate that urinary biomarkers may represent an early sign of PRTD recovery.

Subjects

THAILAND; POTASSIUM metabolism; PHOSPHATE metabolism; BIOMARKERS; CONVALESCENCE; OUTPATIENT services in hospitals; KIDNEY function tests; LONGITUDINAL method; NEPHROTOXICOLOGY; URIC acid; URINALYSIS; TREATMENT effectiveness; TREATMENT duration; FANCONI syndrome; NUCLEOSIDE reverse transcriptase inhibitors; CHRONIC hepatitis B; DISEASE complications; PROGNOSIS; DIAGNOSIS

Publication

BioMed Research International, 2017, Vol 2017, p1

ISSN

2314-6133

Publication type

Academic Journal

DOI

10.1155/2017/4327385

EBSCO Connect | Privacy policy | Terms of use | Copyright | Manage my cookies
Journals | Subjects | Sitemap
© 2025 EBSCO Industries, Inc. All rights reserved